Victor Sandor, M.D.C.M., has served as a member of ADC Therapeutics' board of directors since April 2020. He was most recently Chief Medical Officer at Array BioPharma from 2014 to 2019, prior to its acquisition by Pfizer, where he was instrumental in obtaining approval of Braftovi and Mektovi. Earlier he was Senior Vice President for Global Clinical Development at Incyte, where he played a critical role in the approval of Jakafi, Vice President and Chief Medical Officer for Oncology at Biogen Idec, and held oncology product development roles at AstraZeneca. Dr. Sandor currently serves on the boards of Kymera Therapeutics and Prelude Therapeutics. He received his M.D.C.M. from McGill University and completed fellowship training in Medical Oncology at the National Institutes of Health.